lutikizumab — NDA/BLA submission
H2 2026
Additional data from the Phase 3 INTREPID study, including results from a 36-week blinded extension period, are expected in 2027 and will be used to support regulatory submissions for lutikizumab in hidradenitis suppurativa in the second half of the year.Source filing